Ten key points for maintaining competitiveness in Europe

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has issued a ten-point plan ahead of the meeting of heads of state in Belgium next Thursday Without the pharmaceutical industry, the EU’s trade balance would shift from a surplus of €147 billion to a deficit of €47 billion The sector generates the largest trade surplus […]

Spain attracts hundreds of clinical trials, offering a last hope to thousands of patients: “Without research, we are lost”

Our country is establishing itself as a hub for clinical research, thanks to its public healthcare system: in 2025 alone, more than 900 trials were authorised Silvia is taking part in a phase III trial, which aims to test the effectiveness of a drug in preventing metastasis in triple-negative breast cancer / eldiario.es Silvia was […]

FDA inspections uncover recurring shortcomings in clinical trials worldwide

A study has revealed similar patterns of non-compliance across different countries and calls into question the actual scope of supervision consalud.es A recent analysis published in the international scientific literature focuses on FDA inspections and the agency’s ability to oversee the quality of clinical trials globally, highlighting both their significance and their limitations. The study, […]

The FDA is launching a pilot programme to monitor clinical trials in real time

The initiative aims to speed up the approval of medicines, reduce the administrative burden and boost competitiveness against China consalud.es The US Food and Drug Administration (FDA) has launched an innovative pilot programme to monitor clinical trial data in real time, with the aim of significantly speeding up the approval of new medicines and boosting […]

Fina Lladós: “Europe must take action to avoid falling behind in biomedical research and access to the most innovative medicines”

Farmaindustria held its Annual General Meeting in Madrid on Thursday, during which the Association’s president warned of the risks and uncertainties affecting the sector due to the current geopolitical climate and US trade policies The future European Biotechnology Act will be key to strengthening the innovation ecosystem and attracting new investment, she stated The Association’s […]

The US and China are stepping up the race for global pharmaceutical innovation

An analysis of the scientific literature reveals how geopolitical competition and R&D models are reshaping drug development and access to healthcare consalud.es Pharmaceutical innovation has established itself as one of the main areas of strategic competition between the United States and China, in a context where biomedical research and drug development are intertwined with economic, […]

Experimental drugs: between innovation and clinical uncertainty

The role of applications for new medicines in research and the strategic use of experimental treatments consalud.es The development of investigational drugs is one of the most critical stages in the pharmaceutical industry. From an analysis of the Investigational New Drug Application chapter, it is clear that these compounds, which have not yet been approved […]

The high cost of pharmaceutical failure: when a failed trial affects the entire business strategy

A recent study reveals that failures in drug development not only reduce future revenue, but also affect mergers, market value and investor confidence consalud.es The cost of a pharmaceutical failure goes far beyond the lost investment in research. This is the conclusion of a study published in the *Review of Quantitative Finance and Accounting*, which […]

The FDA warns that 30% of clinical trials in the US do not report their results

The regulator is stepping up pressure on the pharmaceutical and scientific industries to improve transparency consalud.es The FDA has sounded the alarm over a lack of transparency in biomedical research after finding that around 30% of clinical trials registered in the United States have not reported their results. To address this situation, the agency has […]

How the geopolitical situation is affecting medicines in Spain

The development of a new medicine is a long, complex and high-risk process. Every new treatment—from a therapy for diabetes to a drug for a rare disease—is the result of years of research, thousands of professionals involved and a very substantial investment that is funded, to a large extent, by the revenue generated from medicines […]